Meet the team

David Klenerman

"We hope to watch tau aggregates forming in human neurons, so we can determine how they are formed and identify ways to slow this process down or prevent it from happening." David Klenerman
UK DRI Group Leader

Sir David Klenerman is a Professor of Biophysical Chemistry at the University of Cambridge and a Fellow of Christ's College. He is best known for his work on next-generation sequencing of DNA (which subsequently resulted in Solexa, a high-speed DNA sequencing company that he co-founded), receiving the 2020 Millennium Technology Prize and a knighthood in the 2019 New Year Honours for his contribution to this field. Sir David has received a string of honours, including a 2018 Royal Medal from the Royal Society for his outstanding contribution to applied sciences, the 2020 Millenium and he was elected as a Fellow of the Academy of Medical Sciences in 2015 and Fellow of the Royal Society in 2012. Most recently, his group is focusing on super-resolution microscopy to develop new insights on protein misfolding and neurodegenerative diseases, which is the subject of his new programme at the UK DRI.

1. At a glance

Stopping the spread in Alzheimer’s disease

In the brains of people with Alzheimer’s disease (AD) and other related neurodegenerative conditions, a protein called tau builds up and forms abnormal structures. In healthy neurons, tau binds to and stabilises the cell’s scaffolding. But when problems start to arise, the protein molecules behave differently – clumping together and forming toxic aggregates that disrupt the ability of neurons to communicate messages through vital connections called synapses.

Until recently, scientists thought that tau aggregates were only generated through disturbances to the protein production processes within neurons. However, growing evidence now suggests that the abnormal protein molecules themselves are capable of multiplying and spreading through the brain from neuron to neuron via synapses.

Prof David Klenerman is studying the molecular basis of this ‘prion-like’ spreading of tau aggregates using a variety of cutting-edge cell biology techniques. Building a better understanding of the underlying mechanisms involved in tau formation and spread will allow the design of effective new treatments that can slow down, stop or reverse the progression of AD and other neurodegenerative diseases. As an important first step towards this goal, the team aim to develop and test the ability of potential new drugs to stop aggregate formation in their cell systems.

2. Scientific goals

Aggregation of tau into hyperphosphorylated filaments is a defining feature of tauopathies, including Alzheimer’s disease (AD) and corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Pick’s disease (PD). Tau is a highly expressed soluble microtubule-associated protein that plays an important role in the assembly and stability of microtubules. Aggregated tau is typically hyperphosphorylated, and in this form, it loses its physiological role of binding microtubules, and it gains toxic properties. A key role of tau oligomers and filaments in neuronal dysfunction and degeneration is supported by a correlation of the distribution and severity of tau pathology with clinical phenotypes of AD and other tauopathies.

Until recently, cell-autonomous mechanisms were believed to be largely responsible for human neurodegenerative diseases. However, mounting evidence now suggests that protein aggregates involved in at least some of these diseases, including tau aggregates, are capable of self-sustaining amplification that can propagate along neuroanatomical connections, leading to disease progression from restricted brain areas in the early phase of the disease to widespread brain regions in the later stages. This phenomenon is commonly referred to as ‘prion-like’ spreading. Tau aggregates entering a cell can cause the formation of additional tau aggregates, leading to both amplification and cellular damage. The release of protein aggregates from brain cells and their uptake by neighbouring cells then leads to spreading from cell to cell. Propagation of aggregates requires their release into the extracellular space, uptake by connected cells and then seeded aggregation of soluble intracellular proteins. Studying the underlying molecular mechanisms involved in seeding, amplification and spreading may thus lead to the identification of novel therapeutic targets.

Main objectives and research goals:

The team aims to determine the molecular basis of the critical steps in tau aggregation and seeding, exploiting novel biophysical methods that can directly image and characterise full-length tau aggregates in cells and cell lysate. They will explore:

1. In vitro aggregation and disaggregation. Exploring the effects of post-translational modifications on nucleation, seeding and fragmentation of 3R and 4R tau.

2. Aggregation of tau in neurons. Quantitative characterisation of the number, size and type of aggregates formed under different conditions.

3. Disaggregation/degradation of tau aggregates in neurons. Study changes in proteasomal localisation and activity under different conditions.

4. Seeding of tau aggregation in neurons. Characterising changes in number or location of aggregates over time and on cell physiology under different conditions.

5. Spreading of tau aggregates from neuron to neuron. Following aggregate movement using super-resolution imaging using normal cell cultures or microfluidic chambers.

6. Development of elongation and fragmentation inhibitors. Developing inhibitors of the aggregation of full-length tau, identifying which molecular steps are altered and testing the most promising inhibitors in cells.

7. Modelling. Developing robust in vitro models for studying tau aggregation/disaggregation, seeding and spreading.

3. Team members

Dr Jack Brelstaff (Postdoctoral Researcher)
Dr Matthew Cheetham (Postdoctoral Researcher)
Dr Dezerae Cox (Postdoctoral Researcher)
Dr John Danial (Postdoctoral Researcher)
Dr Shekhar Kedia (Postdoctoral Researcher)
Dr Evgeniia Lobanova (Postdoctoral Researcher)
Dr Rohan Ranasinghe (Postdoctoral Researcher)
Dr Georg Meisl (Research Associate)
Tomi Akingbade (PhD Student)
Dorothea Boeken (PhD Student)
Elizabeth English (PhD Student)
Emre Fertan (PhD Student)
Helen Henson (PhD Student)
Bing Li (PhD Student)
Jeff Lam (PhD Student)
Jonathen Meng (PhD Student)
Prasanna Suresh (PhD Student)
Zengjie Xia (PhD Student)
Yu Zhang (PhD Student)
Beatrix Huissoon (PhD Student)
Asher Dworkin (PhD Student)
Kelly Xiong (PhD Student)
Yuhao Cui (PhD Student)
Eva Wong (PhD Student)
Daniel Heraghty (PhD Student)
Florence Layburn (PhD Student)
Woo Suk Yang (Student)

4. Collaborations

Within UK DRI:

  • Prof Henrik Zetterberg, UK DRI at UCL
  • Dr Will McEwan, UK DRI at Cambridge
  • Prof Kei Cho, UK DRI at King's
  • Dr Tim Bartels, UK DRI at UCL
  • Prof Giles Hardingham, UK DRI at Edinburgh
  • Prof Siddharthan Chandran, UK DRI at Edinburgh

Beyond UK DRI:

  • Prof Maria Grazia Spillantini, University of Cambridge
  • Dr Caroline Williams-Gray, University of Cambridge
  • Prof Tuomas Knowles, University of Cambridge
  • Prof Michele Vendruscolo, University of Cambridge
  • Prof Clare Bryant, University of Cambridge
  • Prof Nick Gay, University of Cambridge
  • Prof James Rowe, University of Cambridge
  • Prof Bradley Hyman, Harvard Medical School
  • Dr Matthew Horrocks University of Edinburgh

5. Topics

Protein aggregation, single aggregate imaging, Tau, superresolution imaging, molecular basis of prion-like spreading,

6. Techniques

Super resolution imaging and single molecule tracking, biophysical methods to characterise aggregates, inflammation and TLR4 signalling, chemical kinetics and modelling of aggregation

7. Key publications

Rodrigues, M., Bhattacharjee, P., Brinkmalm, A. et al. Structure-specific amyloid precipitation in biofluids. Nat. Chem. (2022).

Meng, J.X., Zhang, Y., Saman, D. et al. Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. Nat Commun 13, 2692 (2022).

Meisl G, Hidari E, Allinson K, Rittman T, DeVos SL, Sanchez JS, Xu CK, Duff KE, Johnson KA, Rowe JB, Hyman BT, Knowles TPJ, Klenerman D. In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. Sci Adv. 2021 Oct 29;7(44):eabh1448.

Evgeniia Lobanova, Daniel Whiten, Francesco S Ruggeri, Christopher G Taylor, Antonina Kouli, Zengjie Xia, Derya Emin, Yu P Zhang, Jeff Y L Lam, Caroline H Williams-Gray, David Klenerman, Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease, Brain, Volume 145, Issue 2, February 2022, pp. 632–643

Hughes, C., Choi, M.L., Yi, J.H., Kim, S.C., Drews, A., George-Hyslop, P.S., Bryant, C., Gandhi, S., Cho, K. and Klenerman, D., 2020. Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death. Communications biology, 3(1), pp.1-7.

Sang, J.C., Hidari, E., Meisl, G. et al. Super-resolution imaging reveals α-synuclein seeded aggregation in SH-SY5Y cells. Commun Biol 4, 613 (2021).

De, S., Whiten, D.R., Ruggeri, F.S., Hughes, C., Rodrigues, M., Sideris, D.I., Taylor, C.G., Aprile, F.A., Muyldermans, S., Knowles, T.P., Vendruscolo, M.,Bryant, C., Blennow, K., Skoog, I., Kern, S., Zetterberg, H., Klenerman, D., 2019. Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression. Acta neuropathologica communications, 7(1), p.120.

De, S., Wirthensohn, D.C., Flagmeier, P., Hughes, C., Aprile, F.A., Ruggeri, F.S., Whiten, D.R., Emin, D., Xia, Z., Varela, J.A., Sormanni, P., Kundel, F., Knowles, T.P.J., Dobson, C.M., Bryant, C., Vendruscolo, M., Klenerman, D., 2019. Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms. Nature communications, 10(1), pp.1-11.

CD Hughes, ML Choi, M Ryten, L Hopkins, A Drews, JA Botia, M Iljina, M Rodrigues, SA Gagliano, S Gandhi C Bryant, D Klenerman. Picomolar concentrations of oligomeric alpha synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis. Acta Neuropathologica 2019;137(1):103-120